中国医学影像技术
中國醫學影像技術
중국의학영상기술
CHINESE JOURNAL OF MEDICAL IMAGING TECHNOLOGY
2009年
7期
1283-1285
,共3页
张迎强%陈黎波%李方%龙明清%王凤英
張迎彊%陳黎波%李方%龍明清%王鳳英
장영강%진려파%리방%룡명청%왕봉영
嗜铬细胞瘤%体层摄影术,发射型计算机,单光子%3-碘苄胍
嗜鉻細胞瘤%體層攝影術,髮射型計算機,單光子%3-碘芐胍
기락세포류%체층섭영술,발사형계산궤,단광자%3-전변고
Pheochromocytoma%Tomography,emission-computed,single-photon%3-Iodobenzylguanidine
目的 探讨131I-MIBG显像诊断嗜铬细胞瘤的临床价值.方法 430例临床疑似嗜铬细胞瘤的患者接受131I-MIBG全身显像,其中接受B超、CT和MR检查者分别有326、400和77例,接受病理检查者178例. 结果 430例患者中108例确诊为嗜铬细胞瘤,89例131I-MIBG显像阳性,阴性19例.131I-MIBG显像诊断嗜铬细胞瘤的敏感性、特异性和准确性分别为82.41%、100%和95.70%;对单侧肾上腺病灶、双侧肾上腺病灶、异位病灶以及恶性病灶的检出率分别为90.00%(54/60)、45.45%(5/11)、85.71%(24/28)以及66.67%(6/9).在所有患者、同时具有临床症状(高血压或头痛、心悸、大汗三联征中至少一项)和阳性常规影像学检查结果(B超、CT或MR至少一项为阳性)的患者以及同时具有临床症状、阳性24小时尿儿茶酚胺和阳性常规影像学检查结果的患者中,131I-MIBG显像的阳性率分别为20.69%、35.15%以及64.58%,差异有统计学意义.59例肾上腺意外瘤中确诊为嗜铬细胞瘤10例,131I-MIBG显像阳性8例. 结论 131I-MIBG显像是嗜铬细胞瘤首选的确诊方法,但不宜将其作为筛选方法.
目的 探討131I-MIBG顯像診斷嗜鉻細胞瘤的臨床價值.方法 430例臨床疑似嗜鉻細胞瘤的患者接受131I-MIBG全身顯像,其中接受B超、CT和MR檢查者分彆有326、400和77例,接受病理檢查者178例. 結果 430例患者中108例確診為嗜鉻細胞瘤,89例131I-MIBG顯像暘性,陰性19例.131I-MIBG顯像診斷嗜鉻細胞瘤的敏感性、特異性和準確性分彆為82.41%、100%和95.70%;對單側腎上腺病竈、雙側腎上腺病竈、異位病竈以及噁性病竈的檢齣率分彆為90.00%(54/60)、45.45%(5/11)、85.71%(24/28)以及66.67%(6/9).在所有患者、同時具有臨床癥狀(高血壓或頭痛、心悸、大汗三聯徵中至少一項)和暘性常規影像學檢查結果(B超、CT或MR至少一項為暘性)的患者以及同時具有臨床癥狀、暘性24小時尿兒茶酚胺和暘性常規影像學檢查結果的患者中,131I-MIBG顯像的暘性率分彆為20.69%、35.15%以及64.58%,差異有統計學意義.59例腎上腺意外瘤中確診為嗜鉻細胞瘤10例,131I-MIBG顯像暘性8例. 結論 131I-MIBG顯像是嗜鉻細胞瘤首選的確診方法,但不宜將其作為篩選方法.
목적 탐토131I-MIBG현상진단기락세포류적림상개치.방법 430례림상의사기락세포류적환자접수131I-MIBG전신현상,기중접수B초、CT화MR검사자분별유326、400화77례,접수병리검사자178례. 결과 430례환자중108례학진위기락세포류,89례131I-MIBG현상양성,음성19례.131I-MIBG현상진단기락세포류적민감성、특이성화준학성분별위82.41%、100%화95.70%;대단측신상선병조、쌍측신상선병조、이위병조이급악성병조적검출솔분별위90.00%(54/60)、45.45%(5/11)、85.71%(24/28)이급66.67%(6/9).재소유환자、동시구유림상증상(고혈압혹두통、심계、대한삼련정중지소일항)화양성상규영상학검사결과(B초、CT혹MR지소일항위양성)적환자이급동시구유림상증상、양성24소시뇨인다분알화양성상규영상학검사결과적환자중,131I-MIBG현상적양성솔분별위20.69%、35.15%이급64.58%,차이유통계학의의.59례신상선의외류중학진위기락세포류10례,131I-MIBG현상양성8례. 결론 131I-MIBG현상시기락세포류수선적학진방법,단불의장기작위사선방법.
Objective To assess the clinical value of 131I-metaiodobenzylguanidine (MIBG) scintigraphy in pheochromocytoma. Methods A total of 430 patients with clinically suspected pheochromocytoma underwent 131I-MIBG whole body scintigraphy, 326 among them underwent B-ultrasound, 400 for CT and 77 for MR examination respectively. While 178 among them were diagnosed with pathology and the others were diagnosed clinically. Results Of all the patients, 108 were diagnosed pheochromocytoma, including 89 131I-MIBG scan positive and 19 negative. The sensitivity, specificity and accuracy of 131I-MIBG were 82.41%, 100% and 95.70%, respectively. 131I-MIBG scan detected 90.00% of unilateral adrenal, 45.45% of bilateral adrenal, 85.71% of ectopic and 66.67% of malignant lesions, respectively. The proportion of patients with positive 131I-MIBG scan increased from 20.69% in all patients to 35.15% in patients with clinical symptoms and positive conventional imaging (at least one of B-ultrasonography, CT or MR was positive) and 64.58% in those with clinical symptoms, positive conventional imaging, and elevated 24 h urinary catacholamines. In 59 patients with adrenal incidentaloma, 8 were scan-positive and all had confirmed pheochromocytoma, while 2 of scan-negative patients also had confirmed pheochromocytoma. Conclusion 131I-MIBG scintigraphy is the first choice for the diagnosis of both adrenal and extra-adrenal pheochromocytoma. However, it is inappropriate to take this method as the initial screening approach.